Diagnostics
Genetic testing has become an important medical standard for families with known histories of hereditary disease. Individuals who choose to go through the mental and emotional process of taking a genetic test and absorbing the potentially life-changing conclusions may be disturbed to find out that results of such tests are not always consistent.
Sudden unexpected death in epilepsy (SUDEP) occurs in approximately 1/1000 people with epilepsy and is poorly understood
Myriad Genetics, Inc. today announced that that its BRACAnalysis CDx® test accurately identified patients with newly-diagnosed, advanced-stage, BRCA-mutated (BRCAm) ovarian cancer who may benefit from treatment with Lynparza® (olaparib).
Agreement demonstrates growing use of OncoDNA solutions across Europe
Glycotest Inc., Inc. announced today the close of a Series A funding round of $10 million from Shanghai Fosun Pharmaceutical Co., Ltd.
What do you wish someone would’ve told you at the beginning of your career? Most people reflect on their career development and think, ‘If only I knew then what I know now, I’d be farther along.’
Company announces patented blood-based diagnostic test expanding to other autoimmune diseases as well as cancer
Myriad Genetics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved BRACAnalysis CDx® to be used by healthcare professionals to identify patients with HER2-negative metastatic breast cancer (mBC) who have a germline BRCA mutation and are eligible for treatment with Pfizer’s PARP (poly ADP ribose polymerase) inhibitor, TALZENNA® (talazoparib).
DNAe was named ‘Best Diagnostic Medtech Company’ at the 2018 OBN Awards.
Sysmex Inostics is pleased to announce publication of a study in the Journal of Molecular Oncology highlighting the important clinical value of blood-based ctDNA mutation testing to complement standard-of-care management of patients with advanced melanoma.
PRESS RELEASES